Menu Search
Equities

Royalty Pharma PLC

RPD:FRA

Royalty Pharma PLC

Actions
  • Price (EUR)24.40
  • Today's Change0.22 / 0.91%
  • Shares traded4.04k
  • 1 Year change-1.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 14:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Royalty Pharma PLC grew revenues 5.24% from 2.24bn to 2.35bn while net income improved 2,549.50% from 42.83m to 1.13bn.
Gross margin--
Net profit margin75.64%
Operating margin68.13%
Return on assets10.11%
Return on equity17.61%
Return on investment13.30%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Royalty Pharma PLC fell by 1.23bn. However, the company earned 2.99bn from its operations for a Cash Flow Margin of 126.89%. In addition the company used 2.07bn on investing activities and also paid 2.15bn in financing cash flows.
Cash flow per share1.20
Price/Cash flow per share21.52
Book value per share11.63
Tangible book value per share11.63
More ▼

Balance sheet in USDView more

Royalty Pharma PLC has a Debt to Total Capital ratio of 42.58%, a lower figure than the previous year's 99.87%.
Current ratio1.54
Quick ratio--
Total debt/total equity1.11
Total debt/total capital0.4258
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)32.50%
EPS growth(5 years)1.83
EPS (TTM) vs
TTM 1 year ago		543.82
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.